| Biomarker ID | 1995 |
| PMID | 22589488 |
| Year | 2012 |
| Biomarker | Methylation status of PHLDA 3 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Hypermethlated in Recurrent prostate cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Clinical recurrence vs. biochemical recurrence |
| Type of Biomarker | Prognostic |
| Cohort | clinical recurrence (n = 80) versus biochemical recurrence (n = 43) |
| Senstivity | Training: 61.0 (47.4–73.4); Validation:65.6 (40.7–84.6) |
| Specificity | Training:59.0 (42.1–74.4); validation: 65.0 (40.7–84.6) |
| AUC | Training: 0.606; validation:0.73 |
| Accuracy | NA |
| Level Of Significance | <0.0772 |
| Method Used | Pyrosequencing |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | PHLDA 3 |